Skip to main content
. 2014 Apr 4;120(13):2006–2015. doi: 10.1002/cncr.28696

Figure 5.

Figure 5

TumorGraft sensitivity testing is illustrated for Patient 1241 (POS-1241), who was diagnosed with metastatic myxoma. TumorGraft testing demonstrates significant tumor growth inhibition after treatment with a combination of either ifosfamide and etoposide or irinotecan and temozolomide. Asterisks denote significance (triple asterisks indicate P ≤ .001).